Sedana Medical AB (publ) (FRA:7D2A)
Germany flag Germany · Delayed Price · Currency is EUR
0.9640
+0.0030 (0.31%)
At close: Jan 27, 2026

Sedana Medical AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
197.61178.75153.87122.87159.15141.77
Revenue Growth (YoY)
13.48%16.17%25.23%-22.80%12.26%97.88%
Cost of Revenue
58.3652.6144.8936.7952.4552.87
Gross Profit
139.25126.14108.9886.07106.7188.9
Selling, General & Admin
155.22156.6154.74169.94148.31102.42
Research & Development
19.9320.2920.8119.9419.77.86
Other Operating Expenses
0.030.03-0.020.12-0.11-0.02
Operating Expenses
175.18176.92175.53190.01167.9110.26
Operating Income
-35.93-50.78-66.55-103.93-61.2-21.36
Interest Expense
-3.19-0.18-0.22-0.26-0.24-0.19
Interest & Investment Income
5.6816.4915.173.58--
Currency Exchange Gain (Loss)
10.1324.52-7.4227.684.07-2.56
Other Non Operating Income (Expenses)
-15.3-0----0
Pretax Income
-38.61-9.95-59.02-72.93-57.37-24.1
Income Tax Expense
2.040.730.590.570.63.04
Net Income
-40.65-10.67-59.61-73.51-57.97-27.14
Net Income to Common
-40.65-10.67-59.61-73.51-57.97-27.14
Shares Outstanding (Basic)
999999999392
Shares Outstanding (Diluted)
999999999392
Shares Change (YoY)
---6.85%1.54%9.27%
EPS (Basic)
-0.41-0.11-0.60-0.74-0.62-0.30
EPS (Diluted)
-0.41-0.11-0.60-0.74-0.62-0.30
Free Cash Flow
-2.27-13.99-38.58-116.17-46.41-20.29
Free Cash Flow Per Share
-0.02-0.14-0.39-1.17-0.50-0.22
Gross Margin
70.47%70.57%70.83%70.06%67.05%62.71%
Operating Margin
-18.18%-28.41%-43.25%-84.59%-38.45%-15.07%
Profit Margin
-20.57%-5.97%-38.74%-59.83%-36.42%-19.14%
Free Cash Flow Margin
-1.15%-7.82%-25.07%-94.55%-29.16%-14.31%
EBITDA
-34.07-48.77-64.19-100.56-56.8-16.92
EBITDA Margin
-17.24%-27.28%-41.72%-81.84%-35.69%-11.93%
D&A For EBITDA
1.852.012.363.384.44.44
EBIT
-35.93-50.78-66.55-103.93-61.2-21.36
EBIT Margin
-18.18%-28.41%-43.25%-84.59%-38.45%-15.07%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.